XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:        
Total revenue $ 15,735 $ 155,973 $ 106,367 $ 218,766
Operating costs and expenses:        
Cost of goods sold $ 4,308 $ 3,266 $ 15,355 $ 9,746
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 75,182 $ 75,880 $ 235,163 $ 273,123
General and administrative     90,722 89,186
Selling, general and administrative 29,902 25,853    
Total operating costs and expenses 109,392 104,999 341,240 372,055
Income (loss) from operations (93,657) 50,974 (234,873) (153,289)
Interest and other, net        
Interest expense (84) (109) (321) (965)
Interest income and other income (expenses), net 1,798 (1,303) 6,672 (2,120)
Total interest and other, net 1,714 (1,412) 6,351 (3,085)
Income (loss) before income taxes (91,943) 49,562 (228,522) (156,374)
Provision for income taxes 114 106 250 235
Investment income in unconsolidated variable interest entity 407 342 1,293 664
Net income (loss) $ (91,650) $ 49,798 $ (227,479) $ (155,945)
Net income (loss) per share - basic $ (0.98) $ 0.54 $ (2.43) $ (1.69)
Net income (loss) per share - diluted $ (0.98) $ 0.54 $ (2.43) $ (1.69)
Weighted average number of common shares used to calculate net income (loss) per share:        
Basic 93,767 92,644 93,431 92,206
Diluted 93,767 92,808 93,431 92,206
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 116,434 $ 22,590 $ 116,434
Development and Other Revenue [Member]        
Revenue:        
Total revenue 2,453 26,097 19,672 60,325
Product Revenue, Net [Member]        
Revenue:        
Total revenue 17,359 13,442 59,495 42,175
Drug Product Revenue [Member]        
Revenue:        
Total revenue $ (4,077) $ 0 $ 4,610 $ (168)